Testbed 2: Engineered Immune Cells

In Year 6 we expanded the engineered T cell Test-Bed to other immune cells to recognize the emergence of other cellular immunotherapies including NK cells, B cells, macrophages, etc. Test-Bed 2 projects span the entire engineered system, from patient cell procurement to product distribution and delivery. The testbed has been expanded to include engineering and characterization natural killer cells through virus-free payloads. We have also built supply chain models of CAR T cell therapeutics considering real-time patient health status for prioritization of queuing and resource allocation, providing a much-needed platform for ethicists and cell manufacturing stakeholders to test decision-making scenarios.  Specific projects can be found below:

Projects

• On-Chip Cell Therapy Potency Platform (Thrust involved 2,3)
• In-line Multi-omics to Establish Feedback Control within Immune Cell Bioreactor (Thrust involved 1,2,3)
• Patient-Specific Potency Chips to Assess T Cell Quality (Thrust involved 1,2,3)
• Scalable Manufacturing of Gene-Modified Primary Natural Killer Cell Therapies (Thrust involved 1,2,3)
• Development of Novel Supply Chain and Process Modeling Algorithms, Methods, and Tools for Cell Therapy Manufacture and Distribution (Thrust involved 1)
• Label-free isolation of T lymphocytes from leukapheresis products with ultrahigh throughput and resolution (Thrust involved 2)
• Scalable Nanowires to Engineer CAR-T cells and Modulate T Cell Fitness (Thrust involved 2)
• Hyper Redundant Flexible Manipulator (HRFM) "Snake Robot" (Thrust involved 3)
• Developing microfluidic devices to generate gene edited nonactivated CAR T cells (Thrust involved 2)
• Liquid Crystal Droplet-Based Biosensors for Cell Manufacturing Processes (Thrust involved 2)